Specifically, BACE1-AS and DOK2 are strongly related to chemotherapy sensitivity and may serve as predictors of treatment response or targets for overcoming resistance; NMI shows particular promise in molecular subtyping and prognostic assessment; and CLEC12A offers new perspectives for investigating the tumor immune microenvironment and responses to immunotherapy. The gene discussed is DOK2; the disease is neoplasm.